Extent of Resection as the Primary Independent Predictor of Progression- Free Survival in Atypical Intracranial Meningioma: A Retrospective Single- Center Study of 187 Patients
In a retrospective study of 187 patients with atypical intracranial meningioma, the extent of resection was identified as the sole independent predictor of progression-free survival, underscoring maximal safe resection as the primary surgical goal while finding no significant impact from age or radiotherapy.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
The human brain is encased in a protective layer of tissue, and sometimes, new growths form between this layer and the skull itself. These growths, called meningiomas, are the most common type of primary brain tumor found in adults. While the vast majority of these tumors grow slowly and behave like benign neighbors, a specific subset is more aggressive. These are known as atypical meningiomas. They are defined by their tendency to grow faster and, crucially, to return after being removed. Because they can come back, doctors face a difficult challenge: how to predict which patients will remain free of the tumor and which will see it return, and what treatment offers the best chance for a lasting cure.
For decades, the standard approach has been to remove as much of the tumor as safely possible during surgery. The logic is straightforward: if you take out more of the tumor, less remains to grow back. However, even when surgeons believe they have removed the entire mass, some tumors still return. This has led to a debate in the medical community about whether adding radiation therapy after surgery helps prevent that return, or if the key to success lies entirely in the surgeon's skill and the completeness of the removal. To settle this question for atypical meningiomas, a team of researchers at the University Hospital Erlangen in Germany looked back at the records of nearly two hundred patients treated over seven years.
The researchers examined the medical histories of 187 adults who had undergone surgery for atypical intracranial meningiomas between 2016 and 2023. Their goal was to find the factors that truly predicted whether a patient would remain free of tumor progression. They focused on three main variables: how much of the tumor was removed, whether the patient received radiation after the operation, and whether the brain tissue surrounding the tumor showed signs of swelling, known as edema. They also considered the patient's age and general health. By tracking these patients over time, the team could see which of these factors actually correlated with the tumor coming back.
The results offered a clear and decisive answer regarding the surgery. The study found that the extent of the tumor removal was the single most important factor in predicting a patient's outcome. Patients in whom the surgeons were able to remove the entire visible tumor, a state called gross total resection, had significantly better long-term results than those in whom some tumor tissue had to be left behind. In the group where the entire tumor was removed, only about 11 percent experienced a recurrence or progression of the disease. In contrast, among the patients who had a subtotal resection, where some tumor remained, more than 30 percent saw the tumor return. When the researchers analyzed all the data together, accounting for age, health status, and other variables, the amount of tumor left behind remained the only independent predictor of whether the disease would return.
Surprisingly, the study found that postoperative radiation therapy did not significantly improve the odds of keeping the tumor away, at least not in the way the researchers had hoped to measure it. While radiation is often used to kill remaining microscopic cells, the data showed no clear statistical difference in tumor-free survival between patients who received radiation and those who did not. It is important to note that the decision to give radiation was not random; doctors tended to prescribe it for patients who already had more aggressive disease or who had undergone incomplete removal. Even with this higher-risk group receiving the extra treatment, their outcomes were not statistically better than those who did not receive it. This suggests that while radiation is a tool in the arsenal, it does not override the fundamental importance of removing as much of the tumor as possible during the initial surgery.
The researchers also looked at a visual clue often seen on brain scans: swelling around the tumor. This swelling, or edema, is a sign that the tumor is affecting the surrounding brain tissue. The data showed a consistent pattern where patients with this swelling were more likely to experience tumor progression, but the statistical evidence was not strong enough to declare it a definitive predictor. The trend was there, suggesting that edema might be a marker of a more aggressive tumor biology, but the study could not confirm it with absolute certainty. The researchers noted that this finding requires confirmation in larger groups of patients before it can be used to guide treatment decisions. Similarly, the age of the patient and the specific location of the tumor did not show a significant link to whether the tumor would return.
Ultimately, this study reinforces a central principle in neurosurgery: the most effective way to prevent an atypical meningioma from returning is to remove it completely during the first operation. While radiation and other treatments have their place, the data indicates that they cannot compensate for leaving tumor tissue behind. The study also highlights that these tumors are biologically complex; even when removed entirely, they can still return, and factors like surrounding swelling may hold clues to this behavior that are not yet fully understood. For now, the clearest path to a better outcome remains the surgeon's ability to achieve a complete and safe removal, a goal that this large review of patient data confirms is the most powerful tool available for managing these challenging tumors.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.